Christopher Meyer

Experience

• 

  Baxter International Inc.

  Jan 1999 - Jul 2004

  Plant Controller

  Managed the financial operations of two biopharmaceutical manufacturing sites in Los Angeles and Detroit, which produced $475 million in products annually.

• 

  Amgen

  Jul 2004 - Jul 2005

  Manufacturing Financial Planning & Analysis Lead

  Led manufacturing accounting team consolidating results for five manufacturing sites and corporate reporting.

• 

  Baxter International Inc.

  Jul 2005 - Jul 2015

  Drove development of manufacturing strategies and long-range plans to meet the business needs of Baxter BioScience by capturing business, commercial, and pipeline needs for all plasma-derived and biosurgery products, evaluating capabilities, and recommending options and business cases to evolve the manufacturing network. Led long-range capacity planning process for Baxter BioScience to understand manufacturing capabilities and business needs. Developed and maintained manufacturing and financial models to evaluate complex operational decisions, including capacity expansions or consolidations.(Platforms: plasma proteins, recombinant, biosurgery, and vaccines.) Led continuous improvement team for Baxter Los Angeles biopharmaceutical plant in the areas of:• Project management office• Strategy development and business performance management• Continuous improvement (DMAIC, Lean Manufacturing, Industrial Engineering)• Organizational Architecture, Change Management and Communications• New Process Implementation (NPI) optimization

  • Director, Strategic Operations, Plasma Proteins and BioSurgery

    Jul 2011 - Jul 2015

  • Director Strategic Operations and Capital Investment Planning

    Aug 2007 - Jul 2011

  • Director, Operational Excellence and Business Performance

    Jul 2005 - Aug 2007
• 

  Takeda

  Jul 2015 - Apr 2018

  Director Strategic Operations CMC Product Manager, Immunology

  Provided company with an integrated operations product strategy to support business needs and drive its implementation to deliver on the strategic priorities, focusing on Ig (Immunoglobulins) Product Family and other plasma-derived products.Oversaw and managed long-range network capacity and demand planning for plasma proteins manufacturing network, supporting $4.2 billion in product sales.•••••>Led a CMC team to successfully implement, license, and supply CUVITRU®, Immune Globulin Subcutaneous 20% Solution. Show less

• 

  Kite Pharma

  Apr 2018 - Mar 2021

  Director Business Strategic Operations, Oncology Cellular Therapies

  Drove development of Kite’s Technical Operations business strategy, long-range planning, and enterprise business continuity program in collaboration with cross-functional business partners (Commercial, Supply Chain, Manufacturing, Finance, and Capital Planning/Facilities).•••••> Successfully orchestrated global manufacturing site selections (for Kite and Takeda), securing optimal sites in Covington, GA, and Frederick, MD, enabling over $2 billion in investments with substantial local and state financial support.•••••> Established and enhanced a business continuity management program for a cell therapy business, proving vital during the 2020 pandemic, ensuring resilience amid resource challenges. Show less

• 

  Atara Biotherapeutics

  Mar 2021 - Mar 2024

  Director Strategic Operations CMC Project Manager, Oncology Cellular Therapies

  Led and empowered cross-functional CMC team for the Atara ATA188 program, including the development and execution of the end-to-end CMC program strategy.•••••> Accelerated implementation of a new product, enabling an FDA Investigational New Drug amendment and phase 3 trial supply within 12 months, achieving timely readiness and compliance.Accountable for driving organizational performance and transformative initiatives at the network level to meet evolving business needs.•••••> Led the creation of a transformative CMC product commercialization roadmap, providing a crucial stepwise process for streamlined program advancement through clinical stages.•••••> Revolutionized goal setting and performance monitoring, achieving a 95% goal attainment (up from 30% the prior year) by implementing a process in an operations environment that lacked prior active goal management. Show less

• 

  Ospree Consulting Group

  Apr 2024 - now

  Sr Consultant Strategic Operations, Biologics and Cell Therapies

  Focus Areas:Strategy Development | Operations and Supply Planning | Strategic Decision Analysis | CMC program planning/management | Optimization Initiatives | Business Continuity Planning.Chris is an experienced biotherapeutics/cell therapy operations strategic planning and business operations leader. He brings a unique blend of CMC program management, technical operations, finance, and commercialization expertise to the table, which he leverages to address client business needs.Before consulting, he held Director of Strategic Operations roles at Atara Biotherapeutics, Kite Pharma (a Gilead division), and Takeda (formerly Baxter/Baxalta/Shire) in Product and CMC Program Lead roles for clinical and commercial stage products. Show less